Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, improves exercise capacity and quality of life in CTEPH patients. It works by relaxing blood vessels in the lungs, reducing pulmonary vascular resistance.
Clinical trials demonstrate that sildenafil significantly improves 6-minute walk distances. Patients often report a noticeable increase in their daily activity levels.
Sildenafil is typically considered as an adjunctive therapy, often used alongside other treatments like anticoagulation or surgery. Dosage adjustments are common based on individual responses and tolerance, starting with low doses and gradually increasing as needed.
Common side effects include headache, flushing, and visual disturbances. Patients should report any significant side effects to their healthcare provider immediately.
While sildenafil offers a valuable treatment option, it’s crucial to remember that it’s not a cure for CTEPH. Regular monitoring of pulmonary artery pressure and clinical symptoms remains vital throughout the treatment course.
Patients should discuss the potential benefits and risks of sildenafil with their pulmonologist or cardiologist to determine the best course of treatment tailored to their specific condition.
